Sandoz: share price stands out, Deutsche Bank upgrades to buy

(CercleFinance.com) - Sandoz shares rose on Wednesday's trading on the Zurich Stock Exchange following a change of recommendation by analysts at Deutsche Bank, who were optimistic about the biosimilar drugmaker's prospects.


At around 12:00 pm, the stock gained 3.3% after having gained nearly 4%, while the SMIM index of Swiss mid-caps gained 1.1%.

This morning, Deutsche Bank raised its opinion on the stock from 'hold' to 'buy', and also revised upwards its target price from CHF 36 to CHF 42, representing a potential upside of 17%.

In addition to the planned launch of several new biosimilars and the promise of improved margins, analysts believe that the sales growth target of around 5% for 2025 could prove prudent, given the Group's solid performance since its spin-off from Novartis.

Copyright (c) 2025 CercleFinance.com. All rights reserved.